Prescription Opioid Misuse in US Older Adults: Associated Comorbidities and Reduced Quality of Life in the National Epidemiologic Survey of Alcohol and Related Conditions-III

Ty S. Schepis, PhD, a, * and Sean Esteban McCabe, PhD b, c, d

ABSTRACT

Objective: Prescription opioid misuse (POM) prevalence in US older adults (50 years and older) has increased, and preliminary evidence associates POM with poor outcomes. Despite this, little is known about the health-related quality of life, mental and physical health, and substance use profiles of older adults with current and/or past POM. The aim of this study was to evaluate differences in these variables by POM history in US older adults.

Methods: Data were from the 2012–2013 National Epidemiologic Survey of Alcohol and Related Conditions-III, using adults 50 years and older (n = 14,667). Respondents were grouped into mutually exclusive categories: no lifetime POM, prior-to-past-year POM, past-year POM, and persistent POM (ie, prior-to-past-year and past-year POM). Groups were compared using design-based linear regression on health-related quality of life and logistic regression on mental health, physical health, and substance use variables, controlling for sociodemographics.

Results: Older adults with persistent POM had the greatest impairment, including lower mental and physical health–related quality of life and high rates of past-year major depression (17.6%), emergency department use (42.7%), and any substance use disorder (37.4%). Older adults with past-year POM had high rates of physical health diagnoses and health care utilization (eg, 45.6% past-year overnight hospitalization), while those with prior-to-past-year POM had significant current psychopathology (eg, 13.7% with past-year major depression).

Conclusions: Older adults with persistent POM likely need multidisciplinary care for their significant physical and mental health and substance use conditions. Given the elevated psychopathology in those with persistent POM, psychiatrists are well placed to identify those with long-term POM.

J Clin Psychiatry 2019;80(6):19m12853


To share: https://doi.org/10.4088/JCP.19m12853

© Copyright 2019 Physicians Postgraduate Press, Inc.

a Department of Psychology, Texas State University, San Marcos, Texas
b Center for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing, University of Michigan, Ann Arbor, Michigan
c Institute for Research on Women and Gender, University of Michigan, Ann Arbor, Michigan
d Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan

*Corresponding author: Ty S. Schepis, PhD, Department of Psychology, Texas State University, 601 University Dr, San Marcos, TX 78666 (schepis@txstate.edu).

Ty S. Schepis, PhD, a, * and Sean Esteban McCabe, PhD b, c, d

ABSTRACT

Objective: Prescription opioid misuse (POM) prevalence in US older adults (50 years and older) has increased, and preliminary evidence associates POM with poor outcomes. Despite this, little is known about the health-related quality of life, mental and physical health, and substance use profiles of older adults with current and/or past POM. The aim of this study was to evaluate differences in these variables by POM history in US older adults.

Methods: Data were from the 2012–2013 National Epidemiologic Survey of Alcohol and Related Conditions-III, using adults 50 years and older (n = 14,667). Respondents were grouped into mutually exclusive categories: no lifetime POM, prior-to-past-year POM, past-year POM, and persistent POM (ie, prior-to-past-year and past-year POM). Groups were compared using design-based linear regression on health-related quality of life and logistic regression on mental health, physical health, and substance use variables, controlling for sociodemographics.

Results: Older adults with persistent POM had the greatest impairment, including lower mental and physical health–related quality of life and high rates of past-year major depression (17.6%), emergency department use (42.7%), and any substance use disorder (37.4%). Older adults with past-year POM had high rates of physical health diagnoses and health care utilization (eg, 45.6% past-year overnight hospitalization), while those with prior-to-past-year POM had significant current psychopathology (eg, 13.7% with past-year major depression).

Conclusions: Older adults with persistent POM likely need multidisciplinary care for their significant physical and mental health and substance use conditions. Given the elevated psychopathology in those with persistent POM, psychiatrists are well placed to identify those with long-term POM.

J Clin Psychiatry 2019;80(6):19m12853


To share: https://doi.org/10.4088/JCP.19m12853

© Copyright 2019 Physicians Postgraduate Press, Inc.

a Department of Psychology, Texas State University, San Marcos, Texas
b Center for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing, University of Michigan, Ann Arbor, Michigan
c Institute for Research on Women and Gender, University of Michigan, Ann Arbor, Michigan
d Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan

*Corresponding author: Ty S. Schepis, PhD, Department of Psychology, Texas State University, 601 University Dr, San Marcos, TX 78666 (schepis@txstate.edu).
Prescription opioid misuse (POM) in the United States is a public health crisis, with increasing rates of overdose and related fatalities. While the opioid epidemic has shifted somewhat from prescription medication to illicit opioids as drivers of overdose, POM was linked to 17,087 US overdose deaths in 2016. Even when POM does not result in overdose, it is not benign. Across the population, POM is linked with the incidence and recurrence of mood and anxiety disorders, poorer self-reported health and health-related quality of life, greater emergency department (ED) utilization, and higher rates of other substance use and substance use disorders (SUDs).

While POM has received increasing research attention, POM in older adults (50 years and older) remains understudied. Older adults have lower POM rates than younger groups, although older adult POM rates increased significantly from 2002/2003 to 2012/2013. Furthermore, naloxone administration during emergency medical services calls increased by over 100% from 2012 to 2016, and opioid-related substance use treatment rates rose from 2000 to 2012 in US adults 55 years and older. In small convenience samples of older adults, the correlates of POM are similar to those in younger groups: higher levels of problematic substance use and depressive symptoms. In addition, older adults engaged in POM are more likely to misuse their own prescription medication than younger age groups, with high rates of opioid SUD symptoms in those engaged in POM.

Nonetheless, little is known about how POM history in older adults relates to health-related quality of life or psychopathology. Potential relationships between health care utilization (eg, past-year overnight hospitalization) or specific physical health conditions (eg, arthritis) and POM in older adults are also understudied. Finally, greater clarity is needed in patterns of concurrent substance use and SUD among older adults with varying POM histories. Understanding the health-related quality of life, psychopathology, physical health, and substance use profiles of older adults could highlight specific treatment needs in older adults with different POM histories; conversely, specific physical and mental health variables may mark increased POM likelihood, signaling an opportunity for screening and intervention.

**Aims and Hypotheses**

Our primary aim was to evaluate the relationship of a mutually exclusive 4-level lifetime/past-year POM history grouping variable to 4 health domains in older adults: 1, health-related quality of life; 2, mood, anxiety and trauma-related disorders; 3, health care utilization and physical health conditions; and 4, substance use and SUD history. Data were from the National Epidemiologic Survey of Alcohol and Related Conditions-III (NESARC-III), allowing for the first such study using nationally representative data in older adults. We hypothesized that older adults with persistent POM (ie, both past-year and prior-to-past-year) would have the lowest health-related quality of life and highest prevalence rates of psychopathology, health care utilization, physical health conditions, and substance use/SUD. Those with no history of misuse would have the best profiles, while those with only past-year or only prior-to-past-year POM would be intermediate.

**METHODS**

The NESARC-III is a nationally representative survey of noninstitutionalized, nonmilitary US adults, with sampling in both households and group quarters (eg, assisted living). Data collection occurred from April 2012 through May 2013. The NESARC-III used a multistage probability sampling design, with random participant selection, with oversampling of nonwhite individuals. The screening response rate was 72.0%, and the interview response rate was 84.0%. The overall response rate of 60.1% is comparable to other large, nationally representative surveys. Data were weighted to be nationally representative of the US civilian population as of 2012, with adjustments for oversampling and nonresponse. Both the National Institutes of Health and Westat institutional review boards (IRBs) approved the NESARC-III protocol, and the Texas State University IRB exempted this study from oversight. More information on the NESARC-III is available elsewhere.

**Participants**

The NESARC-III included 36,309 US adults. The current sample was restricted to adults 50 years and older (n = 14,667). The weighted older adult sample was 53.3% female and was 75.5% white, non-Hispanic; 10.0% black, non-Hispanic; and 9.0% Hispanic/Latino; 40.4% were 65 years or older. Participants in the weighted older adult sample were most likely to be married (60.9%; 12.6% widowed and 15.0% divorced), with similar proportions of high school and college graduates (23.5% and 29.5%, respectively).

**Measures**

**Prescription opioid misuse group.** POM was assessed in a NESARC-III module on use/misuse of non-alcohol and non-tobacco substances. This module was introduced via the following, read aloud by the field interviewer (emphasis and pauses from the NESARC-III): "Now I'd like to ask you
older adults.29–32 and mental health scales. SF-12 scores are normed to a mean composed of the vitality, social functioning, role-emotional, pain, and general health scales; the mental component is composed of the physical functioning, role-physical, bodily health domains.

These were in 4 categories: health-related quality of life, psychopathology, health care utilization/physical health, and substance use/SUD. Health-related quality of life was based on the 12-Item Short-Form Health Survey version 2 (SF-12v2), a 12-item assessment containing 2, higher-order, component scores (physical and mental) and 8 scale scores. The component scores are composed of 4 scales, with the physical component composed of the physical functioning, role-physical, bodily pain, and general health scales; the mental component is composed of the vitality, social functioning, role-emotional, and mental health scales. SF-12 scores are normed to a mean of 50 and standard deviation of 10, and it is reliable and valid in older adults.29–32

Physopathology was measured using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5), a fully structured self-report measure of DSM-5 diagnoses. Psychopathology included the following (lifetime and past-year): major depression, bipolar I disorder, generalized anxiety disorder, social anxiety disorder, panic disorder, and posttraumatic stress disorder (PTSD). Lifetime suicide attempts (yes/no) were also included. The AUDADIS-5 has fair to good reliability.28,33

Health care utilization variables were any past-year: ED visits, overnight hospitalizations, and injuries requiring medical attention or at least a half-day activity reduction (all yes/no). Seven past-year physical health conditions were assessed: chest pain/angina, arthritis, insomnia, cancer, complex regional pain syndrome, diabetes, and peripheral nerve problems. These were 2-item assessments, with the first question asking whether the participant had the condition in the past year and the second assessing whether a doctor or other health professional [told] you that you had [health condition].” Confirmation by a health professional was required. The physical health conditions were chosen because they are associated with either significant pain (eg, diabetic neuropathy) or a common POM motive (ie, “to sleep”/insomnia).14

Finally, the substance use/SUD variables were lifetime and past-year sedative/tranquilizer misuse, marijuana use, any SUD, alcohol use disorder, tobacco use disorder, and prescription opioid use disorder. Past-year binge alcohol use was included and defined as 4 or 5 alcoholic drinks within a 2-hour period for women and men, respectively.34 The substance use/SUD variables were assessed via the AUDADIS-5, with strong reliability.28

**Table 1. SF-12**a Mean Values in US Older Adults by Opioid Misuse Group

<table>
<thead>
<tr>
<th></th>
<th>No Misuse (A; n = 13,386)</th>
<th>Prior to Past-Year Misuse Only (B; n = 752)</th>
<th>Both Past-Year and Prior Misuse (C; n = 659)</th>
<th>Post Hoc Significant Differences</th>
<th>A vs B, C, D vs B, D</th>
<th>B vs C, D, D vs C, C vs D</th>
<th>C, D vs B</th>
<th>B vs D</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physical disability scale</strong></td>
<td>46.1 (45.7–46.4)</td>
<td>45.5 (44.3–46.7)</td>
<td>41.2 (37.5–44.9)</td>
<td>38.7 (37.7–40.1)</td>
<td>A vs B, C, D vs B, D</td>
<td>B vs C, D</td>
<td>C, D vs B</td>
<td>B vs D</td>
</tr>
<tr>
<td><strong>Physical functioning</strong></td>
<td>47.4 (47.0–47.7)</td>
<td>47.4 (46.3–48.6)</td>
<td>43.2 (38.9–46.7)</td>
<td>40.2 (38.7–41.7)</td>
<td>A vs B, C, D vs B, D</td>
<td>B vs C, D</td>
<td>C, D vs B</td>
<td>B vs D</td>
</tr>
<tr>
<td><strong>Role physical</strong></td>
<td>47.0 (46.7–47.3)</td>
<td>44.9 (44.0–45.9)</td>
<td>40.9 (37.9–43.9)</td>
<td>40.1 (38.8–41.3)</td>
<td>A vs B, C, D vs B, D</td>
<td>B vs C, D</td>
<td>C, D vs B</td>
<td>B vs D</td>
</tr>
<tr>
<td><strong>Bodily pain</strong></td>
<td>47.4 (47.0–47.7)</td>
<td>45.8 (44.5–47.1)</td>
<td>38.6 (34.4–42.7)</td>
<td>36.8 (35.2–38.4)</td>
<td>A vs B, C, D</td>
<td>B vs C, D</td>
<td>C, D vs B</td>
<td>B vs D</td>
</tr>
<tr>
<td><strong>General health</strong></td>
<td>46.6 (46.2–47.0)</td>
<td>44.5 (43.3–45.7)</td>
<td>41.6 (37.6–45.5)</td>
<td>39.5 (38.0–41.0)</td>
<td>A vs B, D</td>
<td>B vs C, D</td>
<td>C, D vs B</td>
<td>B vs D</td>
</tr>
<tr>
<td><strong>Mental disability scale</strong></td>
<td>51.8 (51.5–52.0)</td>
<td>48.3 (47.4–49.2)</td>
<td>44.7 (41.6–47.7)</td>
<td>44.3 (42.9–46.0)</td>
<td>A vs B, C, D vs B, D</td>
<td>B vs C, D</td>
<td>C, D vs B</td>
<td>B vs D</td>
</tr>
<tr>
<td><strong>Vitality</strong></td>
<td>51.1 (50.8–51.3)</td>
<td>49.1 (48.1–50.1)</td>
<td>47.1 (43.8–50.5)</td>
<td>45.4 (44.1–46.7)</td>
<td>A vs B, C, D</td>
<td>B vs C, D</td>
<td>C, D vs B</td>
<td>B vs D</td>
</tr>
<tr>
<td><strong>Social functioning</strong></td>
<td>50.1 (49.8–50.4)</td>
<td>47.5 (46.4–48.7)</td>
<td>43.4 (39.9–47.0)</td>
<td>41.9 (40.3–43.5)</td>
<td>A vs B, C, D</td>
<td>B vs C, D</td>
<td>C, D vs B</td>
<td>B vs D</td>
</tr>
<tr>
<td><strong>Role emotional</strong></td>
<td>47.8 (47.4–48.1)</td>
<td>45.0 (43.9–46.0)</td>
<td>40.9 (36.9–44.9)</td>
<td>39.1 (37.5–40.6)</td>
<td>A vs B, C, D</td>
<td>B vs C, D</td>
<td>C, D vs B</td>
<td>B vs D</td>
</tr>
<tr>
<td><strong>Mental health</strong></td>
<td>52.4 (52.2–52.6)</td>
<td>49.2 (48.2–50.2)</td>
<td>44.1 (40.9–47.3)</td>
<td>45.0 (43.2–46.8)</td>
<td>A vs B, C, D</td>
<td>B vs C, D</td>
<td>C, D vs B</td>
<td>B vs D</td>
</tr>
</tbody>
</table>

*aSF-12 scores are normed to a mean of 50 and standard deviation of 10, and the SF-12 is reliable and valid in older adults. Lower scores indicate lower levels of health, while higher scores indicate higher levels of health. b95% confidence interval of the t score. cPost hoc differences were evaluated via linear regression models adjusted for age, sex, race/ethnicity, U.S. region, educational attainment, marital status, and sexual orientation, and they were Bonferroni-corrected for 6 pairwise comparisons (.05/6 = .0083).

Abbreviation: SF-12 = 12-Item Short-Form Health Survey version 2.

about your experiences with medicines and other kinds of drugs that you may have used ON YOUR OWN—that is, either WITHOUT a doctor’s prescription (PAUSE); in GREATER amounts, MORE OFTEN, or LONGER than prescribed (PAUSE); or for a reason other than a doctor said you should use them. People use these medicines and drugs ON THEIR OWN to feel more alert, to relax or quiet their nerves, to feel better, to enjoy themselves, to get high or just to see how they work.”

Opioid medications were described as “painkillers, for example . . . methadone, codeine, Demerol, Vicodin, Oxy-Contin, opioid, ox, Percocet, Dilaudid, Percodan, morphine.”

For those with lifetime POM, misuse recency was assessed: “Did you use painkillers in the last 12 months only, before the last 12 months only, or during both time periods?” Participants were classified as having no lifetime misuse, prior-to-past-year misuse only, past-year misuse only, or persistent misuse (ie, both prior-to-past-year and past-year misuse).

**Health domains.** These were in 4 categories: health-related quality of life, psychopathology, health care utilization/physical health, and substance use/SUD. Health-related quality of life was based on the 12-Item Short-Form Health Survey version 2 (SF-12v2), a 12-item assessment containing 2, higher-order, component scores (physical and mental) and 8 scale scores. The component scores are composed of 4 scales, with the physical component composed of the physical functioning, role-physical, bodily pain, and general health scales; the mental component is composed of the vitality, social functioning, role-emotional, and mental health scales. SF-12 scores are normed to a mean of 50 and standard deviation of 10, and it is reliable and valid in older adults.29–32

Physopathology was measured using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5), a fully structured self-report measure of DSM-5 diagnoses. Psychopathology included the following (lifetime and past-year): major depression, bipolar I disorder, generalized anxiety disorder, social anxiety disorder, panic disorder, and posttraumatic stress disorder (PTSD). Lifetime suicide attempts (yes/no) were also included. The AUDADIS-5 has fair to good reliability.28,33

Health care utilization variables were any past-year: ED visits, overnight hospitalizations, and injuries requiring medical attention or at least a half-day activity reduction (all yes/no). Seven past-year physical health conditions were assessed: chest pain/angina, arthritis, insomnia, cancer, complex regional pain syndrome, diabetes, and peripheral nerve problems. These were 2-item assessments, with the first question asking whether the participant had the condition in the past year and the second assessing whether a doctor or other health professional [told] you that you had [health condition].” Confirmation by a health professional was required. The physical health conditions were chosen because they are associated with either significant pain (eg, diabetic neuropathy) or a common POM motive (ie, “to sleep”/insomnia).14

Finally, the substance use/SUD variables were lifetime and past-year sedative/tranquilizer misuse, marijuana use, any SUD, alcohol use disorder, tobacco use disorder, and prescription opioid use disorder. Past-year binge alcohol use was included and defined as 4 or 5 alcoholic drinks within a 2-hour period for women and men, respectively.34 The substance use/SUD variables were assessed via the AUDADIS-5, with strong reliability.28

**Data Analyses**

All analyses used Stata 15.1 (College Station, Texas: StataCorp; 2017). Analyses incorporated the complex survey features of the NESARC-III and used data weights and the svy commands. Initially, weighted cross-tabulations were performed to estimate the mean (SF-12/health-related quality of life) or prevalence (psychopathology, physical
health and substance use, and 95% confidence intervals (95\% CIs) of all health domains by POM group.

Following this, linear regression models were fit to evaluate POM group differences in health-related quality of life, and logistic models were fit to estimate between-POM group significant differences in psychopathology, physical health and health care utilization, and substance use prevalence. The linear and logistic models adjusted for age, sex, race/ethnicity, region of the United States, educational attainment, marital status, and sexual orientation. Because these models involved multiple pairwise comparisons, a Bonferroni-adjusted maximum \( P \) value for significance (ie, \( .05/6 \) pairwise comparisons = .0083) was set to reduce the likelihood of Type I (or false positive) error. Sexual orientation was included as a covariate because of evidence that it is significantly associated with POM in older adults.\(^{35}\)

**RESULTS**

**Health-Related Quality of Life by Prescription Opioid Misuse Group**

Those with persistent POM had the lowest SF-12 component and subscale scores (range, 36.8–45.4; Table 1), except for the Mental Health subscale, on which older adults with past-year only misuse were lowest. There were no significant differences between the past-year only (range, 38.6–44.7) and the persistent POM groups or the past-year only and prior-to-past-year only (range, 44.5–49.2) groups. In contrast, the persistent POM group had significantly lower SF-12 scores on all scales than the prior-to-past-year group.

Older adults with no POM history had the highest health-related quality-of-life scores (range, 46.1–52.4), except for the Physical Functioning subscale, on which the no POM and prior-to-past-year POM groups were identical (47.4).

After adjusting for the covariates, the no POM group had significantly higher SF-12 scores than the persistent POM group on all measured scales, higher scores than the prior-to-past-year group on all but Physical Functioning, and higher scores than the past-year only group on both component scores and 5 subscales.

Notably, the persistent POM group had 4 total SF-12 scales/subscales a standard deviation below the mean (Physical Component, 38.7; Bodily Pain, 36.8; General Health, 39.5; and Role-Emotional, 39.1). Given the role of pain in POM, it is important to note that impairment from Bodily Pain decreased from those with persistent POM (36.8) or past-year POM (38.6) to those with prior-to-past-year POM (45.8); higher scores denote a lesser level of pain-related impairment; those with no POM history had significantly less impairment due to bodily pain (ie, higher Bodily Pain scores; 47.4) than other groups.

**Psychopathology by Prescription Opioid Misuse Group**

Per Table 2, those with persistent POM had the highest lifetime and past-year psychopathology rates, while those with no POM history had the lowest. To illustrate, over 1 in 6 with persistent POM had past-year major depression (17.6\%), compared to fewer than 1 in 12 with no POM history (7.9\%). Those with persistent POM had significantly higher rates of psychopathology than those with no POM history for all 6 diagnoses (lifetime or past-year) and lifetime suicide attempts. Prevalence of both lifetime and past-year major depression, PTSD, social anxiety, panic disorder, and lifetime suicide attempts. Prevalence of both lifetime and past-year major depression, PTSD, social anxiety, panic disorder, and lifetime suicide attempts were significantly higher in those with prior-to-past-year POM than those with no history. Finally, those with past-year (only) POM had psychopathology prevalence rates that were most like those with no POM history, with no significant differences from other groups.

---

Table 2. Psychopathology Prevalence Rates in US Older Adults by Opioid Misuse Group

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Lifetime</th>
<th>Past-Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No Misuse</td>
<td>Prior to P-Y</td>
</tr>
<tr>
<td></td>
<td>((n = 13,386))</td>
<td>Misuse Only</td>
</tr>
<tr>
<td>Major depression</td>
<td>18.4 (17.5–19.4)</td>
<td>14.8 (7.5–27.2)</td>
</tr>
<tr>
<td>Bipolar I disorder</td>
<td>1.3 (1.0–1.6)</td>
<td>1.2 (0.2–8.1)</td>
</tr>
<tr>
<td>PTSD</td>
<td>4.5 (4.1–5.0)</td>
<td>6.3 (2.7–14.1)</td>
</tr>
<tr>
<td>Generalized anxiety</td>
<td>7.8 (7.4–8.4)</td>
<td>7.5 (3.4–15.9)</td>
</tr>
<tr>
<td>Social anxiety</td>
<td>3.2 (2.8–3.6)</td>
<td>7.3 (3.2–16.0)</td>
</tr>
<tr>
<td>Panic disorder</td>
<td>4.0 (3.6–4.5)</td>
<td>4.4 (1.3–14.0)</td>
</tr>
<tr>
<td>Suicide attempt</td>
<td>3.5 (3.1–4.0)</td>
<td>3.9 (1.2–12.0)</td>
</tr>
</tbody>
</table>

---

**Abbreviation:** PTSD = posttraumatic stress disorder.
Health Care Utilization and Physical Health by Prescription Opioid Misuse Group

The most impaired physical health and health care utilization profiles were not solely in those with persistent POM (Table 3); instead, prevalence of past-year ED utilization (47.7%) and overnight hospitalizations, (45.6%) and chest pain/angina (18.4%) were highest in those with past-year only POM. Those with persistent POM had significantly higher rates of health care utilization or physical health diagnoses than those with no POM history, and those with persistent POM had higher rates than those with prior-to-past-year POM of all health care utilization and all physical health conditions, except for past-year cancer or complex regional pain. Those with past-year only POM had higher rates of past-year overnight hospitalizations, ED visits, and chest pain/angina than those without a POM history or with prior-to-past-year only POM. No differences were found in diabetes prevalence by POM history.

Substance Use by Prescription Opioid Misuse Group

Per Table 4, those with persistent or prior-to-past-year POM had the highest rates of lifetime substance use or SUD, with significantly higher rates than those with no misuse. Over half of those in the persistent (56.3%) or prior-to-past-year POM (55.6%) groups had a lifetime SUD, while only 1 in 5 (20.5%) of those with no POM history did. For past-year substance use and SUD, highest rates were consistently in those with persistent POM, followed by those with past-year only POM. Nearly 2 in 5 older adults with persistent POM (37.4%) and nearly 3 in 10 with past-year only POM

Table 3. Past-Year Physical Health and Health Care Utilization Prevalence Rates in US Older Adults by Opioid Misuse Group

<table>
<thead>
<tr>
<th></th>
<th>No Misuse (A; n = 13,386)</th>
<th>Prior to Past-Year Misuse Only (B; n = 752)</th>
<th>Past-Year Misuse Only (C; n = 70)</th>
<th>Both Past-Year and Prior Misuse (D; n = 459)</th>
<th>Post Hoc Significant Differencesb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (95% CIa)</td>
<td>% (95% CIa)</td>
<td>% (95% CIa)</td>
<td>% (95% CIa)</td>
<td></td>
</tr>
<tr>
<td>Overnight hospitalizations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16.5 (15.8–17.3)</td>
<td>13.6 (10.7–17.0)</td>
<td>45.6 (32.8–59.0)</td>
<td>31.4 (25.7–37.6)</td>
<td>C, D &gt; A, B</td>
</tr>
<tr>
<td>Emergency department visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>23.1 (22.2–24.1)</td>
<td>24.8 (21.4–28.5)</td>
<td>47.7 (33.0–62.8)</td>
<td>42.7 (37.4–48.2)</td>
<td>C, D &gt; A, B</td>
</tr>
<tr>
<td>Significant injuryc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18.9 (17.9–19.9)</td>
<td>19.5 (16.2–23.2)</td>
<td>27.3 (17.0–40.8)</td>
<td>34.1 (28.4–40.2)</td>
<td>D &gt; A, B</td>
</tr>
<tr>
<td>Chest pain/angina</td>
<td>5.7 (5.3–6.2)</td>
<td>5.6 (3.9–8.2)</td>
<td>18.4 (9.6–32.6)</td>
<td>11.4 (8.3–15.6)</td>
<td>C, D &gt; A, B</td>
</tr>
<tr>
<td>Diabetes</td>
<td>16.9 (16.0–17.8)</td>
<td>13.5 (10.8–16.7)</td>
<td>13.7 (7.8–23.0)</td>
<td>19.2 (15.5–23.6)</td>
<td>No differences</td>
</tr>
<tr>
<td>Arthritis</td>
<td>35.0 (34.2–36.0)</td>
<td>31.5 (27.5–35.8)</td>
<td>39.6 (25.7–55.4)</td>
<td>51.6 (46.2–56.9)</td>
<td>D &gt; A, B</td>
</tr>
<tr>
<td>Insomnia</td>
<td>9.9 (9.2–10.8)</td>
<td>10.8 (8.7–13.4)</td>
<td>10.5 (4.8–21.5)</td>
<td>19.9 (8.0–24.6)</td>
<td>D &gt; A</td>
</tr>
<tr>
<td>Cancer</td>
<td>7.8 (7.5–8.4)</td>
<td>8.4 (6.1–11.6)</td>
<td>8.5 (3.3–20.0)</td>
<td>13.1 (9.7–17.5)</td>
<td>D &gt; A</td>
</tr>
<tr>
<td>Complex regional pain</td>
<td>1.3 (1.0–1.8)</td>
<td>1.2 (0.6–2.5)</td>
<td>1.0 (0.2–12.0)</td>
<td>3.9 (2.2–6.9)</td>
<td>D &gt; A</td>
</tr>
<tr>
<td>Peripheral nerve problems</td>
<td>14.3 (13.4–15.3)</td>
<td>16.1 (12.8–20.2)</td>
<td>28.1 (19.5–38.8)</td>
<td>29.3 (24.8–34.2)</td>
<td>C, D &gt; A, D &gt; B</td>
</tr>
</tbody>
</table>

Table 4. Substance Use Disorder Prevalence Rates in US Older Adults by Opioid Misuse Group

<table>
<thead>
<tr>
<th></th>
<th>No Misuse (A; n = 13,386)</th>
<th>Prior to Past-Year Misuse Only (B; n = 752)</th>
<th>Past-Year Misuse Only (C; n = 70)</th>
<th>Both Past-Year and Prior Misuse (D; n = 459)</th>
<th>Post Hoc Significant Differencesb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (95% CIa)</td>
<td>% (95% CIa)</td>
<td>% (95% CIa)</td>
<td>% (95% CIa)</td>
<td></td>
</tr>
<tr>
<td>Sedative/tranquilizer misuse</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.3 (2.0–2.7)</td>
<td>54.1 (49.3–58.9)</td>
<td>21.2 (14.3–33.9)</td>
<td>52.3 (47.1–57.4)</td>
<td>B, D &gt; C, A</td>
</tr>
<tr>
<td>Marijuana use</td>
<td>22.0 (20.8–23.2)</td>
<td>70.1 (65.1–74.7)</td>
<td>37.3 (25.1–51.4)</td>
<td>52.1 (45.5–58.7)</td>
<td>B, A &gt; C, D, D &gt; A</td>
</tr>
<tr>
<td>Alcohol use disorder</td>
<td>20.5 (19.5–21.5)</td>
<td>55.6 (50.3–60.8)</td>
<td>44.3 (32.2–57.2)</td>
<td>56.3 (49.0–63.2)</td>
<td>B, C, D &gt; A</td>
</tr>
<tr>
<td>Tobacco use disorder</td>
<td>19.3 (18.3–20.3)</td>
<td>48.0 (42.6–53.3)</td>
<td>38.5 (26.4–52.1)</td>
<td>41.0 (34.7–47.7)</td>
<td>B, C, D &gt; A</td>
</tr>
<tr>
<td>Opioid use disorder</td>
<td>24.6 (23.4–25.8)</td>
<td>49.5 (43.9–55.1)</td>
<td>41.2 (29.5–54.0)</td>
<td>48.4 (42.8–54.1)</td>
<td>B, D &gt; A</td>
</tr>
</tbody>
</table>

*95% CI = 95% confidence interval of the prevalence estimate.
*Post hoc differences were evaluated via logistic models adjusted for age, sex, race/ethnicity, US region, educational attainment, marital status, and sexual orientation, and they were Bonferroni-corrected for 6 pairwise comparisons (.05/6 = .0083).
*Significant injury denotes an injury requiring medical care or reduced activities by half a day or more.

For reprints or permissions, contact permissions@psychiatrist.com. © 2019 Copyright Physicians Postgraduate Press, Inc.
(29.7%) had a past-year SUD; this contrasts with the 5.9% rate in those with no POM history. Tobacco use disorder rates were high across those with any history of POM, with lifetime rates in excess of 40% and past-year rates above 30% across groups. Finally, those with persistent POM had the highest rates of both lifetime (29.0%) and past-year (24.3%) prescription opioid SUD.

DISCUSSION

As hypothesized, older adults with persistent POM had impaired health-related quality of life and higher rates of lifetime and past-year psychopathology and substance use/ SUD or past-year health care utilization and physical health conditions. Those with no POM history had the healthiest profiles, including above population mean mental health-related quality of life. Finally, those with prior-to-past-year or past-year POM had intermediate profiles, with unique patterns: psychopathology and lifetime substance use were more common in those with prior-to-past-year POM, while older adults with past-year only POM were more likely to have significant health conditions or health care utilization.

Older adults with persistent POM are a high-risk subgroup likely to require interdisciplinary care to address the common psychopathology, physical health diagnoses, problematic substance use, and impaired quality of life, especially in terms of pain. The SF-12 Bodily Pain subscale suggests that pain significantly interferes with normal functioning in older adults with persistent POM, and multidisciplinary pain management with non-opioid therapies for ongoing pain may be needed. These older adults may also require psychiatric interventions, complex medication management, and other specialist referrals (eg, addiction medicine). Monitoring for suicidality is needed, given their elevated rates of lifetime suicide attempts and recent findings that past-year opioid and/or benzodiazepine medication misuse is associated with suicidal ideation in older adults.

While not currently engaged in POM, those with prior-to-past-year POM still had elevated rates of past-year psychopathology and substance use, relative to those with no misuse history. Over 1 in 10 engaged in past-year marijuana use or binge alcohol use or had an SUD or past-year major depression. While their physical health and health care utilization indicators were very similar to those with no POM history, older adults with prior-to-past-year POM would benefit from screening and may need referrals for psychiatric and/or specialty substance use treatment.

Finally, those with past-year (only) POM had impaired health-related quality of life and higher rates of health care utilization and physical health conditions. While the cross-sectional data preclude causal inference, older adults who recently initiated POM could be self-treating significant physical health problems causing pain, given their notably low SF-12 Bodily Pain scores. Pain relief is the most important motive for most adults engaged in POM, and pain relief may drive POM initiation in older adults; effective pain management may be key to limiting POM in these older adults. Also, screening for SUD is needed in those with any past-year POM, and specialty substance use treatment may be warranted, given that nearly 3 in 10 of the past-year only group had an SUD, often alcohol-related (past-year alcohol use disorder was 19.1%). Finally, elevated rates of sedative/tranquilizer misuse suggest a need to monitor suicidal ideation, as with those with persistent POM.

Clinicians can assess POM risk and current POM using standardized tools, including the Screener and Opioid Assessment for Patients with Pain (SOAPP-R) for POM risk, and Current Opioid Misuse Measure (COMM) for current POM. These measures should be combined with clinical judgment; this appears to increase screening effectiveness. Attention to factors associated with increased POM risk, including the psychiatric, physical health, and substance use correlates examined here, can aid screening efforts.

Limitations

First, the NESARC-III is cross-sectional, and no causal inferences can be made regarding these results. Longitudinal work is needed to clarify these relationships found here, as complex patterns of causal relations or latent third variables (eg, internalizing) may be at work. A second limitation was the secondary analytic nature of the work, with the available sample and variables dictated by the dataset. To illustrate, only 70 older adults were in the past-year POM group, and a lack of results for this group may be due to power-related issues. Future work that examines older adults who recently initiated POM is needed to clarify our results. Third, self-report bias was possible, though research indicates that self-report substance use data are reliable and valid.

Fourth, self-selection bias and undersampling of older adults in controlled access facilities (eg, nursing homes) were both likely to have occurred, with evidence of somewhat poorer coverage of adults 65 years and older. Finally, the k values indicated only fair reliability for the assessed psychopathology, though the substance use assessment had strong reliability.

Summary

US older adults with persistent POM are a group with significant and diverse medical concerns, including low health-related quality of life, psychiatric illness, high rates of health care utilization, and problematic substance use. These adults may strain health care systems and need a multidisciplinary team to address the high likelihood of significant comorbid physical pain and multiple psychiatric and other medical conditions. Nonetheless, the high rates of psychopathology in those with persistent POM also provide an opportunity for screening for POM by psychiatrists and other health care professionals, possibly using the tools suggested above. Completion of a thorough medical history and attention to current physical health complaints can also help psychiatrists screen for more recent initiation (ie, past-year) of POM.

While older adults with past-year only or prior-to-past-year only POM had better profiles than those with persistent


It is illegal to post this copyrighted PDF on any website.

You are prohibited from making this PDF publicly available.
Posttest

To obtain credit, go to PSYCHIATRIST.COM (Keyword: December CME) to take this Posttest and complete the Evaluation. A $10 processing fee is required.

1. According to the study results, individuals aged 50 years or older with past-year prescription opioid misuse (POM) have the highest rates of which of the following, compared with individuals with no misuse, persistent POM (past-year and prior use), and prior-to-past-year-only POM?
   a. Substance use disorders
   b. Major depression
   c. Health care utilization (eg, emergency visits, hospitalizations)
   d. Posttraumatic stress disorder

2. Jamal, a 64-year-old male patient who is nearing retirement from a physically demanding trade, confides in you that he has started taking some of the prescription opioid medication that was prescribed to his wife after surgery she had 6 months ago. He denies ever smoking but acknowledges alcohol use. Which of the following statements about Jamal is false?
   a. He is at risk for impaired health-related quality of life.
   b. He could be self-treating pain and in need of effective pain management.
   c. He is at risk for alcohol use disorder and should be screened.
   d. He is unlikely to need screening for chest pain.